» Articles » PMID: 6819097

Effect of Cyclophosphamide Pretreatment on the Short-term Disposition and Biliary Excretion of Adriamycin Metabolites in Rat

Overview
Specialty Oncology
Date 1982 Dec 1
PMID 6819097
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The effect of pretreatment with cyclophosphamide 180 mg/kg upon the short-term disposition of adriamycin in anesthetized rat 4 days later was studied. There was a significant decrease in plasma adriamycin clearance, from 125 to 48 ml/min/kg, and a significant decrease in the apparent volume of the peripheral compartment of adriamycin distribution, from 51.7 to 25.6 l/kg, in cyclophosphamide-pretreated as against control rats. Biliary excretion of adriamycin over 2.5 h was increased significantly by 114% in cyclophosphamide-pretreated rats and there was a small but nonsignificant increase in biliary adriamycinol excretion and a decrease in excretion of adriamycin aglycones. Cyclophosphamide pretreatment was associated with an 83% increase in bile flow. Cyclophosphamide pretreatment had no significant effect upon the utilization of adriamycin or upon the formation of adriamycin metabolites by rat isolated hepatocytes. The results suggest that NADPH-cytochrome P-450 reductase, which is decreased 40% by cyclophosphamide pretreatment, is not rate-limiting in elimination of adriamycin. Biliary excretion of adriamycin is increased when plasma adriamycin clearance is decreased, suggesting that cyclophosphamide pretreatment affects a pathway besides biliary excretion that is responsible for the short-term removal of adriamycin from plasma.

Citing Articles

Hepatic metabolism of doxorubicin in mice and rats.

Vrignaud P, Robert J Eur J Drug Metab Pharmacokinet. 1986; 11(2):101-5.

PMID: 3770010 DOI: 10.1007/BF03189834.


Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver.

Ballet F, Vrignaud P, Robert J, Rey C, Poupon R Cancer Chemother Pharmacol. 1987; 19(3):240-5.

PMID: 3581417 DOI: 10.1007/BF00252979.


Pharmacokinetic drug interactions of commonly used anticancer drugs.

Balis F Clin Pharmacokinet. 1986; 11(3):223-35.

PMID: 2426030 DOI: 10.2165/00003088-198611030-00004.


Variability in the pharmacokinetics of epirubicin: a population analysis.

Wade J, Kelman A, Kerr D, Robert J, Whiting B Cancer Chemother Pharmacol. 1992; 29(5):391-5.

PMID: 1551178 DOI: 10.1007/BF00686009.

References
1.
Powis G, Svingen B, DeGraw C . Iron-EDTA stimulated reduction of indicine N-oxide by the hepatic microsomal fraction, isolated hepatocytes, and the intact rat. Biochem Pharmacol. 1982; 31(3):293-9. DOI: 10.1016/0006-2952(82)90173-3. View

2.
Bachur N, Gordon S, Gee M, Kon H . NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci U S A. 1979; 76(2):954-7. PMC: 383104. DOI: 10.1073/pnas.76.2.954. View

3.
Driscoll J, Hazard Jr G, WOOD Jr H, Goldin A . Structure-antitumor activity relationships among quinone derivatives. Cancer Chemother Rep 2. 1974; 4(2):1-362. View

4.
Bachur N . Anthracycline antibiotic pharmacology and metabolism. Cancer Treat Rep. 1979; 63(5):817-20. View

5.
Andrews P, Brenner D, Chou F, Kubo H, Bachur N . Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos. 1980; 8(3):152-6. View